TNF inhibitor (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "TNF inhibitor" in English language version.

refsWebsite

Global rank English rank

61nih.gov

4^th place

45doi.org

2^nd place

18semanticscholar.org

11^th place

8^th place

3worldcat.org

5^th place

2harvard.edu

18^th place

17^th place

2drugs.com

399^th place

333^rd place

1web.archive.org

1^st place

1knol.google.com

low place

1fiocruz.br

low place

1medicineworld.org

low place

1psoriasis-association.org.uk

low place

1nice.org.uk

3,258^th place

2,666^th place

1fda.gov

447^th place

338^th place

1creativecommons.org

1,010^th place

612^th place

1bmj.com

1,226^th place

1,421^st place

1science.org

1,160^th place

737^th place

bmj.com

rmdopen.bmj.com

Toussirot, Éric; Aubin, François (2016-07-01). "Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview". RMD Open. 2 (2): e000239. doi:10.1136/rmdopen-2015-000239. ISSN 2056-5933. PMC 4964220. PMID 27493788.

creativecommons.org

Bucalo, Agostino; Rega, Federica; Zangrilli, Arianna; Silvestri, Valentina; Valentini, Virginia; Scafetta, Giorgia; Marraffa, Federica; Grassi, Sara; Rogante, Elena; Piccolo, Arianna; Cucchiara, Salvatore; Viola, Franca; Bianchi, Luca; Ottini, Laura; Richetta, Antonio (January 2020). "Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers". International Journal of Molecular Sciences. 21 (21): 7873. doi:10.3390/ijms21217873. ISSN 1422-0067. PMC 7660646. PMID 33114187. This article incorporates text from this source, which is available under the CC BY 4.0 license.

doi.org

Scheinfeld N (September 2004). "A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab". The Journal of Dermatological Treatment. 15 (5): 280–294. doi:10.1080/09546630410017275. PMID 15370396. S2CID 43332215.
Pappas DA, Bathon JM, Hanicq D, Yasothan U, Kirkpatrick P (September 2009). "Golimumab". Nature Reviews. Drug Discovery. 8 (9): 695–696. doi:10.1038/nrd2982. PMID 19721444.
Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C (May 2002). "Binding and functional comparisons of two types of tumor necrosis factor antagonists". The Journal of Pharmacology and Experimental Therapeutics. 301 (2): 418–426. doi:10.1124/jpet.301.2.418. PMID 11961039. S2CID 43021140.
Essayan DM (November 2001). "Cyclic nucleotide phosphodiesterases". The Journal of Allergy and Clinical Immunology. 108 (5): 671–680. doi:10.1067/mai.2001.119555. PMID 11692087. S2CID 21528985.
Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U (February 1999). "Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages". American Journal of Respiratory and Critical Care Medicine. 159 (2): 508–511. doi:10.1164/ajrccm.159.2.9804085. PMID 9927365.
Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB (June 2006). "A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice". International Immunopharmacology. 6 (6): 903–907. doi:10.1016/j.intimp.2005.12.007. PMID 16644475.
Miller KJ, Gonzalez HA (December 1998). "Serotonin 5-HT2A receptor activation inhibits cytokine-stimulated inducible nitric oxide synthase in C6 glioma cells". Annals of the New York Academy of Sciences. 861 (1): 169–173. Bibcode:1998NYASA.861..169M. doi:10.1111/j.1749-6632.1998.tb10188.x. PMID 9928254. S2CID 23264746.
Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD (November 2008). "Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency". The Journal of Pharmacology and Experimental Therapeutics. 327 (2): 316–323. doi:10.1124/jpet.108.143461. PMID 18708586. S2CID 25374241.
Pelletier M, Siegel RM (December 2009). "Wishing away inflammation? New links between serotonin and TNF signaling". Molecular Interventions. 9 (6): 299–301. doi:10.1124/mi.9.6.5. PMC 2861806. PMID 20048135.
Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (December 1991). "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis". The EMBO Journal. 10 (13): 4025–4031. doi:10.1002/j.1460-2075.1991.tb04978.x. PMC 453150. PMID 1721867.
Brenner D, Blaser H, Mak TW (June 2015). "Regulation of tumour necrosis factor signalling: live or let die". Nature Reviews. Immunology. 15 (6): 362–374. doi:10.1038/nri3834. PMID 26008591. S2CID 1550839.
Ma X, Xu S (March 2013). "TNF inhibitor therapy for rheumatoid arthritis". Biomedical Reports. 1 (2): 177–184. doi:10.3892/br.2012.42. PMC 3956207. PMID 24648915.
Feldmann M, Maini RN (October 2003). "Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases". Nature Medicine. 9 (10): 1245–1250. doi:10.1038/nm939. PMID 14520364. S2CID 52860838.
Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, et al. (January 2008). "Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks". Journal of Immunology. 180 (2): 688–692. doi:10.4049/jimmunol.180.2.688. PMID 18178805. S2CID 45744340.
Haslund P, Lee RA, Jemec GB (November 2009). "Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors". Acta Dermato-Venereologica. 89 (6): 595–600. doi:10.2340/00015555-0747. PMID 19997689.
Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA (January 2017). "TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis". Cytokine. 89: 127–135. doi:10.1016/j.cyto.2016.01.021. PMID 26854213.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. (October 2001). "Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent". The New England Journal of Medicine. 345 (15): 1098–1104. doi:10.1056/NEJMoa011110. PMID 11596589.
Tragiannidis A, Kyriakidis I, Zündorf I, Groll AH (April 2017). "Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors". Mycoses. 60 (4): 222–229. doi:10.1111/myc.12576. PMID 27766695. S2CID 23722641.
"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group". Neurology. 53 (3): 457–465. August 1999. doi:10.1212/WNL.53.3.457. PMID 10449104. S2CID 26126291.
Kemanetzoglou E, Andreadou E (April 2017). "CNS Demyelination with TNF-α Blockers". Current Neurology and Neuroscience Reports. 17 (4): 36. doi:10.1007/s11910-017-0742-1. PMC 5364240. PMID 28337644.
Napolitano M, Balato N, Ayala F, Cirillo T, Balato A (August 2018). "Multiple sclerosis following anti-tumor necrosis factor-alpha therapy for psoriasis: first case in Italy?". Giornale Italiano di Dermatologia e Venereologia. 153 (4): 567–572. doi:10.23736/S0392-0488.17.04992-6. PMID 25692775.
Engel S, Luessi F, Mueller A, Schopf RE, Zipp F, Bittner S (2 January 2020). "PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders". Therapeutic Advances in Neurological Disorders. 13: 1756286419895155. doi:10.1177/1756286419895155. PMC 6940603. PMID 31921355.
Alnasser Alsukhni R, Jriekh Z, Aboras Y (2016-10-20). "Adalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the Literature". Case Reports in Medicine. 2016: 1423131. doi:10.1155/2016/1423131. PMC 5093248. PMID 27840642.
Romeo MA, Garassino MC, Moiola L, Galli G, Comi G, Martinelli V, Filippi M (December 2019). "Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer". Journal of Neurology. 266 (12): 3163–3166. doi:10.1007/s00415-019-09562-z. PMID 31586260. S2CID 203654410.
Kalinowska-Lyszczarz A, Fereidan-Esfahani M, Guo Y, Lucchinetti CF, Tobin WO (August 2020). "Pathological findings in central nervous system demyelination associated with infliximab". Multiple Sclerosis. 26 (9): 1124–1129. doi:10.1177/1352458519894710. PMC 7297659. PMID 31845616.
Garcia CR, Jayswal R, Adams V, Anthony LB, Villano JL (October 2019). "Multiple sclerosis outcomes after cancer immunotherapy". Clinical & Translational Oncology. 21 (10): 1336–1342. doi:10.1007/s12094-019-02060-8. PMC 6702101. PMID 30788836.
Williams I, Uhlig HH (December 2020). "Demyelination After Anti-TNF Therapy: Who is at Risk?". Journal of Crohn's & Colitis. 14 (12): 1651–1652. doi:10.1093/ecco-jcc/jjaa144. PMID 33026456.
Bucalo, Agostino; Rega, Federica; Zangrilli, Arianna; Silvestri, Valentina; Valentini, Virginia; Scafetta, Giorgia; Marraffa, Federica; Grassi, Sara; Rogante, Elena; Piccolo, Arianna; Cucchiara, Salvatore; Viola, Franca; Bianchi, Luca; Ottini, Laura; Richetta, Antonio (January 2020). "Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers". International Journal of Molecular Sciences. 21 (21): 7873. doi:10.3390/ijms21217873. ISSN 1422-0067. PMC 7660646. PMID 33114187. This article incorporates text from this source, which is available under the CC BY 4.0 license.
Vasconcellos, Jaqueline Barbeito de; Pereira, Daniele do Nascimento; Vargas, Thiago Jeunon de Sousa; Levy, Roger Abramino; Pinheiro, Geraldo da Rocha Castelar; Cursi, Ígor Brum (September–October 2016). "Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis". Anais Brasileiros de Dermatologia. 91 (5 suppl 1): 137–139. doi:10.1590/abd1806-4841.20164456. ISSN 0365-0596. PMC 5325021. PMID 28300922.
Toussirot, Éric; Aubin, François (2016-07-01). "Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview". RMD Open. 2 (2): e000239. doi:10.1136/rmdopen-2015-000239. ISSN 2056-5933. PMC 4964220. PMID 27493788.
Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, et al. (July 2006). "The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma". Critical Care Medicine. 34 (7): 1874–1882. doi:10.1097/01.CCM.0000221921.71300.BF. PMID 16715036. S2CID 71135736.
Okunieff P, Xu J, Hu D, Liu W, Zhang L, Morrow G, et al. (July 2006). "Curcumin protects against radiation-induced acute and chronic cutaneous toxicity in mice and decreases mRNA expression of inflammatory and fibrogenic cytokines". International Journal of Radiation Oncology, Biology, Physics. 65 (3): 890–898. doi:10.1016/j.ijrobp.2006.03.025. PMID 16751071.
Gulcubuk A, Altunatmaz K, Sonmez K, Haktanir-Yatkin D, Uzun H, Gurel A, Aydin S (February 2006). "Effects of curcumin on tumour necrosis factor-alpha and interleukin-6 in the late phase of experimental acute pancreatitis". Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine. 53 (1): 49–54. doi:10.1111/j.1439-0442.2006.00786.x. PMID 16411910.
Lantz RC, Chen GJ, Solyom AM, Jolad SD, Timmermann BN (June 2005). "The effect of turmeric extracts on inflammatory mediator production". Phytomedicine. 12 (6–7): 445–452. doi:10.1016/j.phymed.2003.12.011. PMID 16008121.
Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO (August 2007). "Cannabidiol--recent advances". Chemistry & Biodiversity. 4 (8): 1678–1692. doi:10.1002/cbdv.200790147. PMID 17712814. S2CID 3689072.
Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J, Faller B, et al. (May 2006). "Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects". The Journal of Biological Chemistry. 281 (20): 14192–14206. doi:10.1074/jbc.M601074200. PMID 16547349. S2CID 1570400.
Nkadimeng SM, Steinmann CM, Eloff JN (2021). "Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells". Journal of Inflammation Research. 14: 3729–3738. doi:10.2147/JIR.S317182. PMC 8352634. PMID 34385833.
Nau F, Yu B, Martin D, Nichols CD (2013-10-02). "Serotonin 5-HT2A receptor activation blocks TNF-α mediated inflammation in vivo". PLOS ONE. 8 (10): e75426. Bibcode:2013PLoSO...875426N. doi:10.1371/journal.pone.0075426. PMC 3788795. PMID 24098382.
Umar S, Hedaya O, Singh AK, Ahmed S (September 2015). "Thymoquinone inhibits TNF-α-induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation". Toxicology and Applied Pharmacology. 287 (3): 299–305. doi:10.1016/j.taap.2015.06.017. PMC 4549173. PMID 26134265.
Farkhondeh T, Samarghandian S, Shahri AM, Samini F (2018). "The Neuroprotective Effects of Thymoquinone: A Review". Dose-Response. 16 (2): 1559325818761455. doi:10.1177/1559325818761455. PMC 5898665. PMID 29662431.
Ali MY, Akter Z, Mei Z, Zheng M, Tania M, Khan MA (February 2021). "Thymoquinone in autoimmune diseases: Therapeutic potential and molecular mechanisms". Biomedicine & Pharmacotherapy. 134: 111157. doi:10.1016/j.biopha.2020.111157. PMID 33370631. S2CID 229714190.
Malik S, Singh A, Negi P, Kapoor VK (November 2021). "Thymoquinone: A small molecule from nature with high therapeutic potential". Drug Discovery Today. 26 (11): 2716–2725. doi:10.1016/j.drudis.2021.07.013. PMID 34303824. S2CID 236431672.
Vilcek J (July 2008). "First demonstration of the role of TNF in the pathogenesis of disease". Journal of Immunology. 181 (1): 5–6. doi:10.4049/jimmunol.181.1.5. PMID 18566362. S2CID 44529219.
Beutler B, Milsark IW, Cerami AC (July 2008). "Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science, 1985, 229(4716):869-871. Classical article". Journal of Immunology. 181 (1): 7–9. doi:10.1126/science.3895437. PMID 18566363.
Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. (October 1994). "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis". Lancet. 344 (8930): 1105–1110. doi:10.1016/S0140-6736(94)90628-9. PMID 7934491. S2CID 22776233.

drugs.com

"FDA Alert: Tumor Necrosis Factor (TNF) blockers, Azathioprine and/or Mercaptopurine: Update on Reports of Hepatosplenic T-Cell Lymphoma in Adolescents and Young Adults". drugs.com. Retrieved 16 April 2018.
"FDA Alert: Tumor Necrosis Factor-alpha (TNFα) Blockers: Label Change - Boxed Warning Updated for Risk of Infection from Legionella and Listeria". drugs.com. Retrieved 16 April 2018.

fda.gov

"FDA: Manufacturers of TNF-Blocker Drugs Must Highlight Risk of Fungal Infections" (Press release). U.S. Food and Drug Administration (FDA). September 4, 2008. Retrieved 2009-11-15.

fiocruz.br

arca.fiocruz.br

Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB (June 2006). "A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice". International Immunopharmacology. 6 (6): 903–907. doi:10.1016/j.intimp.2005.12.007. PMID 16644475.

harvard.edu

ui.adsabs.harvard.edu

Miller KJ, Gonzalez HA (December 1998). "Serotonin 5-HT2A receptor activation inhibits cytokine-stimulated inducible nitric oxide synthase in C6 glioma cells". Annals of the New York Academy of Sciences. 861 (1): 169–173. Bibcode:1998NYASA.861..169M. doi:10.1111/j.1749-6632.1998.tb10188.x. PMID 9928254. S2CID 23264746.
Nau F, Yu B, Martin D, Nichols CD (2013-10-02). "Serotonin 5-HT2A receptor activation blocks TNF-α mediated inflammation in vivo". PLOS ONE. 8 (10): e75426. Bibcode:2013PLoSO...875426N. doi:10.1371/journal.pone.0075426. PMC 3788795. PMID 24098382.

knol.google.com

"Top Ten/Twenty Best Selling Drugs 2009". Archived from the original on 2011-09-17. Retrieved 2011-09-08.

medicineworld.org

"A new view of drugs used to treat rheumatoid arthritis from medicineworld.org". medicineworld.org. Retrieved 16 April 2018.

nice.org.uk

"Infliximab and adalimumab for the treatment of Crohn's disease | 1-guidance | Guidance and guidelines | NICE". www.nice.org.uk. 19 May 2010. Retrieved 2016-12-04.

nih.gov

pubmed.ncbi.nlm.nih.gov

Scheinfeld N (September 2004). "A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab". The Journal of Dermatological Treatment. 15 (5): 280–294. doi:10.1080/09546630410017275. PMID 15370396. S2CID 43332215.
Pappas DA, Bathon JM, Hanicq D, Yasothan U, Kirkpatrick P (September 2009). "Golimumab". Nature Reviews. Drug Discovery. 8 (9): 695–696. doi:10.1038/nrd2982. PMID 19721444.
Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C (May 2002). "Binding and functional comparisons of two types of tumor necrosis factor antagonists". The Journal of Pharmacology and Experimental Therapeutics. 301 (2): 418–426. doi:10.1124/jpet.301.2.418. PMID 11961039. S2CID 43021140.
Essayan DM (November 2001). "Cyclic nucleotide phosphodiesterases". The Journal of Allergy and Clinical Immunology. 108 (5): 671–680. doi:10.1067/mai.2001.119555. PMID 11692087. S2CID 21528985.
Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U (February 1999). "Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages". American Journal of Respiratory and Critical Care Medicine. 159 (2): 508–511. doi:10.1164/ajrccm.159.2.9804085. PMID 9927365.
Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB (June 2006). "A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice". International Immunopharmacology. 6 (6): 903–907. doi:10.1016/j.intimp.2005.12.007. PMID 16644475.
Miller KJ, Gonzalez HA (December 1998). "Serotonin 5-HT2A receptor activation inhibits cytokine-stimulated inducible nitric oxide synthase in C6 glioma cells". Annals of the New York Academy of Sciences. 861 (1): 169–173. Bibcode:1998NYASA.861..169M. doi:10.1111/j.1749-6632.1998.tb10188.x. PMID 9928254. S2CID 23264746.
Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD (November 2008). "Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency". The Journal of Pharmacology and Experimental Therapeutics. 327 (2): 316–323. doi:10.1124/jpet.108.143461. PMID 18708586. S2CID 25374241.
Pelletier M, Siegel RM (December 2009). "Wishing away inflammation? New links between serotonin and TNF signaling". Molecular Interventions. 9 (6): 299–301. doi:10.1124/mi.9.6.5. PMC 2861806. PMID 20048135.
Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (December 1991). "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis". The EMBO Journal. 10 (13): 4025–4031. doi:10.1002/j.1460-2075.1991.tb04978.x. PMC 453150. PMID 1721867.
Brenner D, Blaser H, Mak TW (June 2015). "Regulation of tumour necrosis factor signalling: live or let die". Nature Reviews. Immunology. 15 (6): 362–374. doi:10.1038/nri3834. PMID 26008591. S2CID 1550839.
Ma X, Xu S (March 2013). "TNF inhibitor therapy for rheumatoid arthritis". Biomedical Reports. 1 (2): 177–184. doi:10.3892/br.2012.42. PMC 3956207. PMID 24648915.
Feldmann M, Maini RN (October 2003). "Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases". Nature Medicine. 9 (10): 1245–1250. doi:10.1038/nm939. PMID 14520364. S2CID 52860838.
Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, et al. (January 2008). "Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks". Journal of Immunology. 180 (2): 688–692. doi:10.4049/jimmunol.180.2.688. PMID 18178805. S2CID 45744340.
Haslund P, Lee RA, Jemec GB (November 2009). "Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors". Acta Dermato-Venereologica. 89 (6): 595–600. doi:10.2340/00015555-0747. PMID 19997689.
Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA (January 2017). "TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis". Cytokine. 89: 127–135. doi:10.1016/j.cyto.2016.01.021. PMID 26854213.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. (October 2001). "Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent". The New England Journal of Medicine. 345 (15): 1098–1104. doi:10.1056/NEJMoa011110. PMID 11596589.
Tragiannidis A, Kyriakidis I, Zündorf I, Groll AH (April 2017). "Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors". Mycoses. 60 (4): 222–229. doi:10.1111/myc.12576. PMID 27766695. S2CID 23722641.
"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group". Neurology. 53 (3): 457–465. August 1999. doi:10.1212/WNL.53.3.457. PMID 10449104. S2CID 26126291.
Kemanetzoglou E, Andreadou E (April 2017). "CNS Demyelination with TNF-α Blockers". Current Neurology and Neuroscience Reports. 17 (4): 36. doi:10.1007/s11910-017-0742-1. PMC 5364240. PMID 28337644.
Napolitano M, Balato N, Ayala F, Cirillo T, Balato A (August 2018). "Multiple sclerosis following anti-tumor necrosis factor-alpha therapy for psoriasis: first case in Italy?". Giornale Italiano di Dermatologia e Venereologia. 153 (4): 567–572. doi:10.23736/S0392-0488.17.04992-6. PMID 25692775.
Mansouri B, Horner ME, Menter A (August 2015). "Tumor Necrosis Factor-α Inhibitor Use in Psoriasis Patients With a First-degree Relative With Multiple Sclerosis". Journal of Drugs in Dermatology. 14 (8): 876–878. PMID 26267733.
Engel S, Luessi F, Mueller A, Schopf RE, Zipp F, Bittner S (2 January 2020). "PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders". Therapeutic Advances in Neurological Disorders. 13: 1756286419895155. doi:10.1177/1756286419895155. PMC 6940603. PMID 31921355.
Alnasser Alsukhni R, Jriekh Z, Aboras Y (2016-10-20). "Adalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the Literature". Case Reports in Medicine. 2016: 1423131. doi:10.1155/2016/1423131. PMC 5093248. PMID 27840642.
Romeo MA, Garassino MC, Moiola L, Galli G, Comi G, Martinelli V, Filippi M (December 2019). "Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer". Journal of Neurology. 266 (12): 3163–3166. doi:10.1007/s00415-019-09562-z. PMID 31586260. S2CID 203654410.
Kalinowska-Lyszczarz A, Fereidan-Esfahani M, Guo Y, Lucchinetti CF, Tobin WO (August 2020). "Pathological findings in central nervous system demyelination associated with infliximab". Multiple Sclerosis. 26 (9): 1124–1129. doi:10.1177/1352458519894710. PMC 7297659. PMID 31845616.
Garcia CR, Jayswal R, Adams V, Anthony LB, Villano JL (October 2019). "Multiple sclerosis outcomes after cancer immunotherapy". Clinical & Translational Oncology. 21 (10): 1336–1342. doi:10.1007/s12094-019-02060-8. PMC 6702101. PMID 30788836.
Williams I, Uhlig HH (December 2020). "Demyelination After Anti-TNF Therapy: Who is at Risk?". Journal of Crohn's & Colitis. 14 (12): 1651–1652. doi:10.1093/ecco-jcc/jjaa144. PMID 33026456.
Bucalo, Agostino; Rega, Federica; Zangrilli, Arianna; Silvestri, Valentina; Valentini, Virginia; Scafetta, Giorgia; Marraffa, Federica; Grassi, Sara; Rogante, Elena; Piccolo, Arianna; Cucchiara, Salvatore; Viola, Franca; Bianchi, Luca; Ottini, Laura; Richetta, Antonio (January 2020). "Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers". International Journal of Molecular Sciences. 21 (21): 7873. doi:10.3390/ijms21217873. ISSN 1422-0067. PMC 7660646. PMID 33114187. This article incorporates text from this source, which is available under the CC BY 4.0 license.
Vasconcellos, Jaqueline Barbeito de; Pereira, Daniele do Nascimento; Vargas, Thiago Jeunon de Sousa; Levy, Roger Abramino; Pinheiro, Geraldo da Rocha Castelar; Cursi, Ígor Brum (September–October 2016). "Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis". Anais Brasileiros de Dermatologia. 91 (5 suppl 1): 137–139. doi:10.1590/abd1806-4841.20164456. ISSN 0365-0596. PMC 5325021. PMID 28300922.
Toussirot, Éric; Aubin, François (2016-07-01). "Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview". RMD Open. 2 (2): e000239. doi:10.1136/rmdopen-2015-000239. ISSN 2056-5933. PMC 4964220. PMID 27493788.
Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, et al. (July 2006). "The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma". Critical Care Medicine. 34 (7): 1874–1882. doi:10.1097/01.CCM.0000221921.71300.BF. PMID 16715036. S2CID 71135736.
Okunieff P, Xu J, Hu D, Liu W, Zhang L, Morrow G, et al. (July 2006). "Curcumin protects against radiation-induced acute and chronic cutaneous toxicity in mice and decreases mRNA expression of inflammatory and fibrogenic cytokines". International Journal of Radiation Oncology, Biology, Physics. 65 (3): 890–898. doi:10.1016/j.ijrobp.2006.03.025. PMID 16751071.
Gulcubuk A, Altunatmaz K, Sonmez K, Haktanir-Yatkin D, Uzun H, Gurel A, Aydin S (February 2006). "Effects of curcumin on tumour necrosis factor-alpha and interleukin-6 in the late phase of experimental acute pancreatitis". Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine. 53 (1): 49–54. doi:10.1111/j.1439-0442.2006.00786.x. PMID 16411910.
Lantz RC, Chen GJ, Solyom AM, Jolad SD, Timmermann BN (June 2005). "The effect of turmeric extracts on inflammatory mediator production". Phytomedicine. 12 (6–7): 445–452. doi:10.1016/j.phymed.2003.12.011. PMID 16008121.
Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO (August 2007). "Cannabidiol--recent advances". Chemistry & Biodiversity. 4 (8): 1678–1692. doi:10.1002/cbdv.200790147. PMID 17712814. S2CID 3689072.
Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J, Faller B, et al. (May 2006). "Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects". The Journal of Biological Chemistry. 281 (20): 14192–14206. doi:10.1074/jbc.M601074200. PMID 16547349. S2CID 1570400.
Nkadimeng SM, Steinmann CM, Eloff JN (2021). "Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells". Journal of Inflammation Research. 14: 3729–3738. doi:10.2147/JIR.S317182. PMC 8352634. PMID 34385833.
Nau F, Yu B, Martin D, Nichols CD (2013-10-02). "Serotonin 5-HT2A receptor activation blocks TNF-α mediated inflammation in vivo". PLOS ONE. 8 (10): e75426. Bibcode:2013PLoSO...875426N. doi:10.1371/journal.pone.0075426. PMC 3788795. PMID 24098382.
Umar S, Hedaya O, Singh AK, Ahmed S (September 2015). "Thymoquinone inhibits TNF-α-induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation". Toxicology and Applied Pharmacology. 287 (3): 299–305. doi:10.1016/j.taap.2015.06.017. PMC 4549173. PMID 26134265.
Farkhondeh T, Samarghandian S, Shahri AM, Samini F (2018). "The Neuroprotective Effects of Thymoquinone: A Review". Dose-Response. 16 (2): 1559325818761455. doi:10.1177/1559325818761455. PMC 5898665. PMID 29662431.
Ali MY, Akter Z, Mei Z, Zheng M, Tania M, Khan MA (February 2021). "Thymoquinone in autoimmune diseases: Therapeutic potential and molecular mechanisms". Biomedicine & Pharmacotherapy. 134: 111157. doi:10.1016/j.biopha.2020.111157. PMID 33370631. S2CID 229714190.
Malik S, Singh A, Negi P, Kapoor VK (November 2021). "Thymoquinone: A small molecule from nature with high therapeutic potential". Drug Discovery Today. 26 (11): 2716–2725. doi:10.1016/j.drudis.2021.07.013. PMID 34303824. S2CID 236431672.
Vilcek J (July 2008). "First demonstration of the role of TNF in the pathogenesis of disease". Journal of Immunology. 181 (1): 5–6. doi:10.4049/jimmunol.181.1.5. PMID 18566362. S2CID 44529219.
Beutler B, Milsark IW, Cerami AC (July 2008). "Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science, 1985, 229(4716):869-871. Classical article". Journal of Immunology. 181 (1): 7–9. doi:10.1126/science.3895437. PMID 18566363.
Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. (October 1994). "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis". Lancet. 344 (8930): 1105–1110. doi:10.1016/S0140-6736(94)90628-9. PMID 7934491. S2CID 22776233.

ncbi.nlm.nih.gov

Pelletier M, Siegel RM (December 2009). "Wishing away inflammation? New links between serotonin and TNF signaling". Molecular Interventions. 9 (6): 299–301. doi:10.1124/mi.9.6.5. PMC 2861806. PMID 20048135.
Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (December 1991). "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis". The EMBO Journal. 10 (13): 4025–4031. doi:10.1002/j.1460-2075.1991.tb04978.x. PMC 453150. PMID 1721867.
Ma X, Xu S (March 2013). "TNF inhibitor therapy for rheumatoid arthritis". Biomedical Reports. 1 (2): 177–184. doi:10.3892/br.2012.42. PMC 3956207. PMID 24648915.
Kemanetzoglou E, Andreadou E (April 2017). "CNS Demyelination with TNF-α Blockers". Current Neurology and Neuroscience Reports. 17 (4): 36. doi:10.1007/s11910-017-0742-1. PMC 5364240. PMID 28337644.
Engel S, Luessi F, Mueller A, Schopf RE, Zipp F, Bittner S (2 January 2020). "PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders". Therapeutic Advances in Neurological Disorders. 13: 1756286419895155. doi:10.1177/1756286419895155. PMC 6940603. PMID 31921355.
Alnasser Alsukhni R, Jriekh Z, Aboras Y (2016-10-20). "Adalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the Literature". Case Reports in Medicine. 2016: 1423131. doi:10.1155/2016/1423131. PMC 5093248. PMID 27840642.
Kalinowska-Lyszczarz A, Fereidan-Esfahani M, Guo Y, Lucchinetti CF, Tobin WO (August 2020). "Pathological findings in central nervous system demyelination associated with infliximab". Multiple Sclerosis. 26 (9): 1124–1129. doi:10.1177/1352458519894710. PMC 7297659. PMID 31845616.
Garcia CR, Jayswal R, Adams V, Anthony LB, Villano JL (October 2019). "Multiple sclerosis outcomes after cancer immunotherapy". Clinical & Translational Oncology. 21 (10): 1336–1342. doi:10.1007/s12094-019-02060-8. PMC 6702101. PMID 30788836.
Bucalo, Agostino; Rega, Federica; Zangrilli, Arianna; Silvestri, Valentina; Valentini, Virginia; Scafetta, Giorgia; Marraffa, Federica; Grassi, Sara; Rogante, Elena; Piccolo, Arianna; Cucchiara, Salvatore; Viola, Franca; Bianchi, Luca; Ottini, Laura; Richetta, Antonio (January 2020). "Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers". International Journal of Molecular Sciences. 21 (21): 7873. doi:10.3390/ijms21217873. ISSN 1422-0067. PMC 7660646. PMID 33114187. This article incorporates text from this source, which is available under the CC BY 4.0 license.
Vasconcellos, Jaqueline Barbeito de; Pereira, Daniele do Nascimento; Vargas, Thiago Jeunon de Sousa; Levy, Roger Abramino; Pinheiro, Geraldo da Rocha Castelar; Cursi, Ígor Brum (September–October 2016). "Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis". Anais Brasileiros de Dermatologia. 91 (5 suppl 1): 137–139. doi:10.1590/abd1806-4841.20164456. ISSN 0365-0596. PMC 5325021. PMID 28300922.
Toussirot, Éric; Aubin, François (2016-07-01). "Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview". RMD Open. 2 (2): e000239. doi:10.1136/rmdopen-2015-000239. ISSN 2056-5933. PMC 4964220. PMID 27493788.
Nkadimeng SM, Steinmann CM, Eloff JN (2021). "Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells". Journal of Inflammation Research. 14: 3729–3738. doi:10.2147/JIR.S317182. PMC 8352634. PMID 34385833.
Nau F, Yu B, Martin D, Nichols CD (2013-10-02). "Serotonin 5-HT2A receptor activation blocks TNF-α mediated inflammation in vivo". PLOS ONE. 8 (10): e75426. Bibcode:2013PLoSO...875426N. doi:10.1371/journal.pone.0075426. PMC 3788795. PMID 24098382.
Umar S, Hedaya O, Singh AK, Ahmed S (September 2015). "Thymoquinone inhibits TNF-α-induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation". Toxicology and Applied Pharmacology. 287 (3): 299–305. doi:10.1016/j.taap.2015.06.017. PMC 4549173. PMID 26134265.
Farkhondeh T, Samarghandian S, Shahri AM, Samini F (2018). "The Neuroprotective Effects of Thymoquinone: A Review". Dose-Response. 16 (2): 1559325818761455. doi:10.1177/1559325818761455. PMC 5898665. PMID 29662431.

psoriasis-association.org.uk

"Psoriasis Association". psoriasis-association.org.uk. Retrieved 16 April 2018.

science.org

Beutler B, Milsark IW, Cerami AC (July 2008). "Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science, 1985, 229(4716):869-871. Classical article". Journal of Immunology. 181 (1): 7–9. doi:10.1126/science.3895437. PMID 18566363.

semanticscholar.org

api.semanticscholar.org

Scheinfeld N (September 2004). "A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab". The Journal of Dermatological Treatment. 15 (5): 280–294. doi:10.1080/09546630410017275. PMID 15370396. S2CID 43332215.
Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C (May 2002). "Binding and functional comparisons of two types of tumor necrosis factor antagonists". The Journal of Pharmacology and Experimental Therapeutics. 301 (2): 418–426. doi:10.1124/jpet.301.2.418. PMID 11961039. S2CID 43021140.
Essayan DM (November 2001). "Cyclic nucleotide phosphodiesterases". The Journal of Allergy and Clinical Immunology. 108 (5): 671–680. doi:10.1067/mai.2001.119555. PMID 11692087. S2CID 21528985.
Miller KJ, Gonzalez HA (December 1998). "Serotonin 5-HT2A receptor activation inhibits cytokine-stimulated inducible nitric oxide synthase in C6 glioma cells". Annals of the New York Academy of Sciences. 861 (1): 169–173. Bibcode:1998NYASA.861..169M. doi:10.1111/j.1749-6632.1998.tb10188.x. PMID 9928254. S2CID 23264746.
Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD (November 2008). "Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency". The Journal of Pharmacology and Experimental Therapeutics. 327 (2): 316–323. doi:10.1124/jpet.108.143461. PMID 18708586. S2CID 25374241.
Brenner D, Blaser H, Mak TW (June 2015). "Regulation of tumour necrosis factor signalling: live or let die". Nature Reviews. Immunology. 15 (6): 362–374. doi:10.1038/nri3834. PMID 26008591. S2CID 1550839.
Feldmann M, Maini RN (October 2003). "Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases". Nature Medicine. 9 (10): 1245–1250. doi:10.1038/nm939. PMID 14520364. S2CID 52860838.
Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, et al. (January 2008). "Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks". Journal of Immunology. 180 (2): 688–692. doi:10.4049/jimmunol.180.2.688. PMID 18178805. S2CID 45744340.
Tragiannidis A, Kyriakidis I, Zündorf I, Groll AH (April 2017). "Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors". Mycoses. 60 (4): 222–229. doi:10.1111/myc.12576. PMID 27766695. S2CID 23722641.
"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group". Neurology. 53 (3): 457–465. August 1999. doi:10.1212/WNL.53.3.457. PMID 10449104. S2CID 26126291.
Romeo MA, Garassino MC, Moiola L, Galli G, Comi G, Martinelli V, Filippi M (December 2019). "Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer". Journal of Neurology. 266 (12): 3163–3166. doi:10.1007/s00415-019-09562-z. PMID 31586260. S2CID 203654410.
Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, et al. (July 2006). "The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma". Critical Care Medicine. 34 (7): 1874–1882. doi:10.1097/01.CCM.0000221921.71300.BF. PMID 16715036. S2CID 71135736.
Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO (August 2007). "Cannabidiol--recent advances". Chemistry & Biodiversity. 4 (8): 1678–1692. doi:10.1002/cbdv.200790147. PMID 17712814. S2CID 3689072.
Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J, Faller B, et al. (May 2006). "Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects". The Journal of Biological Chemistry. 281 (20): 14192–14206. doi:10.1074/jbc.M601074200. PMID 16547349. S2CID 1570400.
Ali MY, Akter Z, Mei Z, Zheng M, Tania M, Khan MA (February 2021). "Thymoquinone in autoimmune diseases: Therapeutic potential and molecular mechanisms". Biomedicine & Pharmacotherapy. 134: 111157. doi:10.1016/j.biopha.2020.111157. PMID 33370631. S2CID 229714190.
Malik S, Singh A, Negi P, Kapoor VK (November 2021). "Thymoquinone: A small molecule from nature with high therapeutic potential". Drug Discovery Today. 26 (11): 2716–2725. doi:10.1016/j.drudis.2021.07.013. PMID 34303824. S2CID 236431672.
Vilcek J (July 2008). "First demonstration of the role of TNF in the pathogenesis of disease". Journal of Immunology. 181 (1): 5–6. doi:10.4049/jimmunol.181.1.5. PMID 18566362. S2CID 44529219.
Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. (October 1994). "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis". Lancet. 344 (8930): 1105–1110. doi:10.1016/S0140-6736(94)90628-9. PMID 7934491. S2CID 22776233.

web.archive.org

"Top Ten/Twenty Best Selling Drugs 2009". Archived from the original on 2011-09-17. Retrieved 2011-09-08.

worldcat.org

search.worldcat.org

Bucalo, Agostino; Rega, Federica; Zangrilli, Arianna; Silvestri, Valentina; Valentini, Virginia; Scafetta, Giorgia; Marraffa, Federica; Grassi, Sara; Rogante, Elena; Piccolo, Arianna; Cucchiara, Salvatore; Viola, Franca; Bianchi, Luca; Ottini, Laura; Richetta, Antonio (January 2020). "Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers". International Journal of Molecular Sciences. 21 (21): 7873. doi:10.3390/ijms21217873. ISSN 1422-0067. PMC 7660646. PMID 33114187. This article incorporates text from this source, which is available under the CC BY 4.0 license.
Vasconcellos, Jaqueline Barbeito de; Pereira, Daniele do Nascimento; Vargas, Thiago Jeunon de Sousa; Levy, Roger Abramino; Pinheiro, Geraldo da Rocha Castelar; Cursi, Ígor Brum (September–October 2016). "Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis". Anais Brasileiros de Dermatologia. 91 (5 suppl 1): 137–139. doi:10.1590/abd1806-4841.20164456. ISSN 0365-0596. PMC 5325021. PMID 28300922.
Toussirot, Éric; Aubin, François (2016-07-01). "Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview". RMD Open. 2 (2): e000239. doi:10.1136/rmdopen-2015-000239. ISSN 2056-5933. PMC 4964220. PMID 27493788.